Davy Research

Mainstay Medical (MSTY.I, MSTY ID)

  • 133.3
  • 8.8
  • 40.4

Company Profile

Mainstay Medical is a specialist medtech company that is developing an innovative therapy (ReActiv8) with the potential to address the physiological origins of chronic, non-specific, low back pain. Management has applied for a CE mark for its ReActiv8 device following the successful completion of European clinical trials, paving the way for commercialisation in Europe in 2016. Prospective US approval, after a pivotal trial, could be achieved two to three years thereafter. With the addressable market for ReActiv8 estimated to be approaching 2m people across the US and EU markets, market size should not be a barrier to growth (while acknowledging competitive therapies). Commercial success can help Mainstay become a specialist medtech company with an increasingly attractive asset in a highly acquisitive sector.


Major Shareholders%
Sofinnova Capital27.5
KCK Ltd18.0
Fountain Healthcare Partners10.7
Capricorn Health-tech Fund6.1
Dan Sachs5.9
  • MAINSTAY MEDICAL

    Closing Price (c): 1520.0

  • RATING 14/09/17

  • PREVIOUS RATING

Analyst(S)

COMPANY DATA

UPCOMING EVENTS

  • There are no upcomming events at present